2,3,3a,4,5,6,7,7a-八氢-1H-茚-5-醇 | 3716-38-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,3,3a,4,5,6,7,7a-八氢-1H-茚-5-醇
• 英文名称: 5-Hydroxy-perhydroindan
• 英文别名: Hydrindanol-(5)；Bicyclo[4.3.0]nonanol-3a；Octahydro-1h-inden-5-ol；2,3,3a,4,5,6,7,7a-octahydro-1H-inden-5-ol
• CAS: 3716-38-9
• 化学式: C₉H₁₆O
• mdl: MFCD00021263
• 分子量: 140.225
• InChiKey: IGRYUSXMPCQPHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906199090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : HEXAHYDRO-5-INDANOL,TECH.
CAS-No. : 3716-38-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to respiratory system and skin. Risk of serious damage to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R37/38 Irritating to respiratory system and skin.
R41 Risk of serious damage to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S39 Wear eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C9H16O
Molecular Weight : 140,23 g/mol
Component Concentration
HEXAHYDRO-5-INDANOL,TECH.
CAS-No. 3716-38-9 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Precautions for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with
multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to
engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting/freezing point no data available
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,471
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Specific target organ toxicity - single exposure
May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes eye burns.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
Mobility in soil
Results of PBT and vPvB assessment
no data available
Other adverse effects
Harmful to aquatic life.

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN-Number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for users
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3,3a,4,5,6,7,7a-八氢-1H-茚-5-醇 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 乙醚 为溶剂， 生成 (+/-)-(cis-octahydro-inden-3a-yl)-methanol
  参考文献：
  名称：

  Koch,H.; Haaf,W., Chemische Berichte, 1961, vol. 94, p. 1252 - 1259

  摘要：

  DOI：
• 作为产物：
  描述：

  3a,4,7,7a-Tetrahydro-1H-inden 在 μ-(η⁵: η⁵-fulvalene)-di-μ-hydrido-bis(cyclopenkadienyltitanium) 、 铂 9-borabicyclo[3.3.1]nonane dimer 、 氢气 作用下， 生成 2,3,3a,4,5,6,7,7a-八氢-1H-茚-5-醇
  参考文献：
  名称：

  A regiospecific double bond shift induced by titanocene catalysts

  摘要：

  DOI：

  10.1016/s0040-4039(01)85579-9

文献信息

• BICYCLIC COMPOUND
  申请人：Yamashita Tohru

  公开号：US20110263562A1

  公开（公告）日：2011-10-27

  The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

  本发明提供了一种具有ACC抑制作用的化合物，该化合物可用作预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症、癌症等的药剂，并具有优越的疗效。 本发明涉及一种由式(I)表示的化合物： 其中每个符号如规范中定义。
• CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS
  申请人：Meyer Imke

  公开号：US20130137710A1

  公开（公告）日：2013-05-30

  The present invention relates to the cosmetic, dermatological or therapeutic use of certain cyclohexyl carbamate compounds of formula (I) given below, preferably as anti-cellulite actives. The invention further relates to compositions and cosmetic, dermatological or therapeutic products comprising such compounds of formula (I), which are preferably suitable for the prophylaxis (prevention) and cosmetic treatment (combating) of cellulite in human beings, corresponding methods and novel compounds of formula (I) wherein A denotes wherein X, Y and Z independently of one another denote hydrogen, C1-C4-alkyl or C2-C4-alkenyl, wherein optionally two of the radicals X, Y and Z are covalently bonded to one another under formation of a bicyclic ring system, in such a bicyclic ring system two of the radicals X, Y and Z together preferably form a radical having 1 to 4 carbon atoms, preferably a hydrocarbon radical having 1 to 3 carbon atoms, B denotes NR 1 R 2 , wherein R 1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R 2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R 1 and R 2 are covalently bonded to one another, preferably so that B is a 3 to 8 membered ring.

  本发明涉及以下式子（I）所示的某些环己基氨基甲酸酯化合物的化妆品、皮肤科或治疗用途，优选作为抗脂肪纹活性剂。本发明还涉及包含该式（I）化合物的组合物和化妆品、皮肤科或治疗产品，这些化合物优选用于人类的脂肪纹预防和美容治疗，以及相应的方法和新型式（I）化合物。其中，A表示......，X、Y和Z分别独立地表示氢、C1-C4烷基或C2-C4烯基，其中可选地，X、Y和Z中的两个基团彼此共价结合形成二环环系统，在这样的二环环系统中，X、Y和Z中的两个基团一起优选形成具有1至4个碳原子的基团，优选为具有1至3个碳原子的碳氢基团，B表示NR1R2，其中R1表示氢或具有1至14个碳原子的有机基团，R2表示具有1至14个碳原子的有机基团，可选地，R1和R2彼此共价结合，优选使得B为3至8个成员的环。
• CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES
  申请人：Vielhaber Gabriele

  公开号：US20130156710A1

  公开（公告）日：2013-06-20

  The present invention relates to the cosmetic, dermatological or therapeutic use of certain cyclohexyl carbamate compounds of formula (I) given below, preferably as skin and/or hair lightening (whitening) actives. The invention further relates to compositions and cosmetic, dermatological or therapeutic products comprising one or more compounds of formula (I) suitable for lightening human skin and/or hair and corresponding methods. The invention further relates to compounds of formula (I) as a drug, their use for the preparation of a pharmaceutical composition for lightening human skin and/or hair and to novel compounds of formula (I) wherein A denotes wherein X, Y and Z independently of one another denote hydrogen, C1-C4-alkyl or C2-C4-alkenyl, wherein optionally two of the radicals X, Y and Z are covalently bonded to one another under formation of a bicyclic ring system, in such a bicyclic ring system two of the radicals X, Y and Z together preferably form a radical having 1 to 4 carbon atoms, preferably a hydrocarbon radical having 1 to 3 carbon atoms, B denotes NR 1 , R 2 , wherein R 1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R 2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R 1 and R 2 are covalently bonded to one another, preferably so that B is a 3 to 8 membered ring.

  本发明涉及以下式子(I)所示的某些环己基氨基甲酸酯化合物的化妆品、皮肤学或治疗用途，优选作为皮肤和/或头发美白活性剂。本发明还涉及含有一个或多个式(I)化合物的组合物和化妆品、皮肤学或治疗产品，适用于美白人类皮肤和/或头发以及相应的方法。本发明还涉及式(I)化合物作为药物，其用于制备用于美白人类皮肤和/或头发的制药组合物，以及式(I)的新化合物，其中A表示其中X、Y和Z彼此独立地表示氢、C1-C4烷基或C2-C4烯基，其中可选地，X、Y和Z中的两个基团在形成二环环系的情况下共价键结在一起，这样，在这样的二环环系中，X、Y和Z中的两个基团首选形成具有1到4个碳原子的基团，优选为具有1到3个碳原子的碳氢基团；B表示NR1、R2，其中R1表示氢或具有1到14个碳原子的有机基团，R2表示具有1到14个碳原子的有机基团，可选地，R1和R2彼此共价键结，优选使得B为3到8个成员的环。
• Cyclohexyl carbamate compounds as anti-ageing actives
  申请人：Symrise AG

  公开号：EP2389922A1

  公开（公告）日：2011-11-30

  The present invention relates to the cosmetic, dermatological or therapeutic use of compounds of formula (I) given below, in particular as anti-ageing actives. wherein A denotes wherein X, Y and Z independently of one another denote hydrogen, C1-C4-alkyl or C2-C4-alkenyl, wherein optionally two of the radicals X, Y and Z are covalently bonded to one another under formation of a bicyclic ring system, in such a bicyclic ring system two of the radicals X, Y and Z together preferably form a radical having 1 to 4 carbon atoms, preferably a hydrocarbon radical having 1 to 3 carbon atoms, B denotes NR1R2, wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that B is a 3 to 8 membered ring. The invention further relates to corresponding methods and to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) and one or more further anti-ageing actives. The invention further relates to compounds of formula (I) as a drug, their use for the preparation of a pharmaceutical composition and to certain novel compounds of formula (I).

  本发明涉及以下式子(I)的化合物在化妆品、皮肤科或治疗中的使用，特别是作为抗衰老活性物质。 其中， A代表 其中，X、Y和Z分别独立地表示氢、C1-C4烷基或C2-C4烯基， 其中，可选地，X、Y和Z中的两个基团在形成二环环系的同时共价键合在一起，这样，在这样的二环环系中，X、Y和Z中的两个基团一起优选形成具有1到4个碳原子的基团，优选是指1到3个碳原子的碳氢基团， B代表NR1R2， 其中， R1代表氢或具有1到14个碳原子的有机基团， R2代表具有1到14个碳原子的有机基团， 并且可选地，R1和R2共价键合在一起，优选是使B成为3到8成员环。 本发明还涉及相应的方法、包含一个或多个式(I)化合物和一个或多个进一步的抗衰老活性物质的组合物和化妆品、皮肤科或制药制剂(组合物)。本发明还涉及式(I)化合物作为药物、其用于制备制药组合物以及某些新的式(I)化合物。
• S1P Modulating Agents
  申请人：Thomas Jermaine

  公开号：US20140371209A1

  公开（公告）日：2014-12-18

  Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

  式(I)或(II)的化合物可以调节SIP受体的活性。